Bloomage Biotechnology Corp Ltd
Bloomage BioTechnology Corporation Limited researchers, develops, produces, and sells bioactive materials. It offers pharmaceutical grade sodium hyaluronate which can be used as an API or excipient for drugs and medical devices in ophthalmic preparations, intra-articular injections, anti-adhesive preparations, and topical preparations for wound healing and soft tissue filler under the Hyature nam… Read more
Bloomage Biotechnology Corp Ltd (688363) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.38 Billion CNY
Based on the latest financial reports, Bloomage Biotechnology Corp Ltd (688363) has total liabilities worth CN¥1.38 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bloomage Biotechnology Corp Ltd - Total Liabilities Trend (2012–2024)
This chart illustrates how Bloomage Biotechnology Corp Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bloomage Biotechnology Corp Ltd Competitors by Total Liabilities
The table below lists competitors of Bloomage Biotechnology Corp Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MakeMyTrip Limited
NASDAQ:MMYT
|
USA | $2.14 Billion |
|
Wuxi Rural Commercial Bank Co Ltd
SHG:600908
|
China | CN¥254.94 Billion |
|
Hangzhou Zhongheng Electric Co Ltd
SHE:002364
|
China | CN¥1.45 Billion |
|
Mando Corp
KO:204320
|
Korea | ₩3.18 Trillion |
|
Net263 Ltd
SHE:002467
|
China | CN¥377.05 Million |
|
Tennant Company
NYSE:TNC
|
USA | $614.20 Million |
|
Pexa Group Ltd
AU:PXA
|
Australia | AU$540.95 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Bloomage Biotechnology Corp Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bloomage Biotechnology Corp Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bloomage Biotechnology Corp Ltd (2012–2024)
The table below shows the annual total liabilities of Bloomage Biotechnology Corp Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.82 Billion | +22.22% |
| 2023-12-31 | CN¥1.49 Billion | -25.63% |
| 2022-12-31 | CN¥2.00 Billion | +10.96% |
| 2021-12-31 | CN¥1.80 Billion | +189.28% |
| 2020-12-31 | CN¥622.68 Million | +47.52% |
| 2019-12-31 | CN¥422.11 Million | +19.39% |
| 2018-12-31 | CN¥353.56 Million | +44.10% |
| 2017-12-31 | CN¥245.35 Million | -42.07% |
| 2016-12-31 | CN¥423.53 Million | -57.95% |
| 2015-12-31 | CN¥1.01 Billion | +373.01% |
| 2014-12-31 | CN¥212.94 Million | +4.40% |
| 2013-12-31 | CN¥203.96 Million | +109.65% |
| 2012-12-31 | CN¥97.29 Million | -- |